Pharming Group N.V. ADS each representing 10 (PHAR)
PHAR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/0001828316-26-000015-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PHAR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | Not reported by the screener |
| SEC CIK | 0001828316 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Netherlands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $376.1M |
| Net income | $2.9M |
| Operating income | $25.8M |
| Net margin | 0.8% |
| Operating margin | 6.9% |
| Revenue growth | +26.6% |
| Cash | $145.3M |
| Total assets | $500.0M |
| P/E (computed) | 311.9× |
| P/S (computed) | 2.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-02 |
| Cash and burn | $145.3M cash; operating cash flow $13.7M a quarter. | Report 2025-12-31 |
| Shares outstanding | 70,168,044 (2025-12-31); 68,030,874 a year earlier; 65,634,823 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Accountants B.V., Eindhoven, Netherlands | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $376.1M | $2.9M | $54.7M | $145.3M | No debt tags | $376.1M | 20-F 2026-04-02 |
| FY 2024 2024-12-31 | $297.2M | -$11.8M | -$1.8M | $54.9M | No debt tags | $297.2M | 20-F 2026-04-02 |
| FY 2023 2023-12-31 | $245.3M | -$10.5M | -$17.3M | $61.7M | No debt tags | $245.3M | 20-F 2026-04-02 |
| FY 2022 2022-12-31 | $205.6M | $13.7M | $22.5M | $207.3M | No debt tags | $205.6M | 20-F 2025-04-03 |
| FY 2021 2021-12-31 | $198.9M | $16.0M | $37.8M | $191.9M | No debt tags | $198.9M | 20-F 2024-04-04 |
| FY 2020 2020-12-31 | $212.2M | $37.7M | $83.6M | $205.2M | No debt tags | $212.2M | 20-F 2023-04-05 |
| FY 2019 2019-12-31 | $189.4M | $40.6M | $74.1M | $74.3M | No debt tags | $189.4M | 20-F 2022-04-06 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2020-12-23 |
| Latest annual report | 20-F | 2026-04-02 |
| Latest quarterly / interim | 6-K | 2026-11-06 |
Source: SEC EDGAR submissions feed, 149 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.5% |
| 1 month | +33.5% |
| 3 months | +2.0% |
| Year to date | -28.7% |
| 1 year | -28.5% |
| From 52-week high | -40.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals Inc. | $10.60 | -0.38% | $894.1M |
| AKTS | Aktis Oncology Inc. | $16.16 | -2.77% | $901.7M |
| CTY | City Therapeutics Inc. | $16.98 | -6.19% | $854.6M |
| LTGO | Latigo Biotherapeutics Inc. | $12.60 | -3.89% | $835.4M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
| JBIO | Jade Biosciences Inc. | $15.34 | -4.99% | $975.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier